Life sciences leaders are increasingly adopting AI and AI agents to address growing industry disruption. This shift is occurring as the sector confronts new regulatory demands that strain compliance teams, increasingly complex clinical trials, and rising expectations from healthcare professionals. A recent Salesforce study revealed that life sciences leaders see AI as a powerful tool for navigating these challenges, with 94% expecting AI agents to be critical for scaling organizational capacity and strengthening operations.
The 50-page study benchmarked the UK against international peers on 48 competitiveness indicators and found foreign investment in life sciences had slumped to £795 million in 2023-58 per cent below 2017 levels-pushing Britain down to seventh place in global rankings from a high of second only two years earlier. Pharmaceutical R&D has also slowed markedly, growing at just 1.9 per cent annually since 2020, against a global average of 6.6 per cent.
Cornell has secured a 10-year, $10 million grant renewal to continue work aimed at spurring economic impact and job growth through applied research, development and commercialization of breakthrough technologies.
In the life sciences industry, regulatory compliance is not just a legal obligation-it's a foundational pillar of product safety, patient health, and organizational integrity.
As a socially conscious developer, we want to engage proactively with our neighbours across Tower Hamlets to promote the exciting opportunities that life sciences will bring to this part of London.